Navigation Links
The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
Date:9/6/2007

Free, Interactive Workshop Features CML Expert, Jorge Cortes, M.D.

WHITE PLAINS, N.Y., Sept. 6 /PRNewswire/ -- Jorge Cortes, M.D., an expert on leukemia, will discuss novel treatment approaches for chronic myelogenous leukemia (CML) in a free telephone workshop entitled CML: A Model in Cancer Therapy. The program is scheduled for Thursday, Sept. 20, 2007, 12:00 p.m. - 1:00 p.m. ET.

The program is being offered by The Leukemia & Lymphoma Society, the leading source of information and support for patients battling leukemia, lymphoma and myeloma, and is supported by an unrestricted educational grant from Novartis.

Dr. Cortes is the deputy chair for the department of leukemia and professor of medicine and internist at The University of Texas M.D. Anderson Cancer Center in Houston, TX. His presentation will address the latest treatment options, emerging therapies, the role of clinical trials and quality of life considerations. A question-and-answer period will follow.

"Dr. Cortes will discuss the promising advances in CML treatment, and provide guidance on the importance of monitoring CML treatment and progress," says Robin Kornhaber, M.S.W., The Leukemia & Lymphoma Society's senior vice president of patient services.

The program is approved for 1.0 Continuing Education Unit for nurses and social workers upon verification of completion.

Registration

Registrants will receive an information packet and toll-free dial-in number within 48 hours of signing up. Participants can register online through http://www.lls.org/cmllinks or by phone at (866) 992-9950 ext. 302.

About Chronic Myelogenous Leukemia

CML is called by several names, including chronic granulocytic, chronic myelocytic or chronic myeloid leukemia. CML results from a change to the DNA of a stem cell in the marrow. Scientists do not yet understand what produces this change in the DNA, which is not present at birth.

The stem cell's changed DNA gives the malignant (cancerous) cell a growth and survival advantage over a normal stem cell. The resulting uncontrolled growth of white cells, if left untreated, will lead to a massive increase in their concentration in the blood. CML does not completely interfere with the development of mature red cells, white cells and platelets; these cells can generally continue to function normally. This is an important distinction from acute leukemia and accounts for the less severe early course of chronic leukemias.

About 4,570 people in the United States will learn they have CML in 2007 in the United States. About 21,501 people in the United States are living with CML. There will be an estimated 490 deaths from CML this year.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The Society's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call the Society's Information Resource Center (IRC), a call center staffed by master's level oncology social workers and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

CONTACT: Andrea Greif

(914) 821-8958


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. GLEEVEC - An Oral treatment for leukemia
2. GLEEVEC - An Oral treatment for leukemia
3. Cyclosporin A Treats Leukemia Complications
4. Aspirin Lowers Leukemia Risk
5. Skin Allergies Found To Increase The Risk Of Leukemia
6. Night Light Found To Increase The Risk Of Leukemia
7. Treating Leukemia With Natural Cells
8. Exposure to EMF may cause leukemia
9. A new vaccine for leukemia
10. Leukemia pill shows promise against stomach cancer
11. Hope for Chemo-Resistant Leukemia Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... Today, Illuma Care Connections, a ... during the 2017 Annual HIMSS Conference & Exhibition in Orlando, Florida, ... and integrating eye care into mainstream healthcare delivery is powered by Secure ...
(Date:2/19/2017)... ... 19, 2017 , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals made ... reveal any logo with a glitch reveal in just a few clicks of a mouse. ... animation of each preset. Use these presets to add a uniquely animated logo to any ...
(Date:2/18/2017)... Waltham, Massachusetts (PRWEB) , ... February 17, 2017 ... ... be the leading source of disruptive innovation in the industry, according to the ... Insights Reports are based on surveys of the NEJM Catalyst Insights Council, a ...
(Date:2/18/2017)... CA (PRWEB) , ... February 18, 2017 , ... ... paragraph presets. Use Pixel Film Studios ’ ProParagraph Fashion Volume 2 ... and so many other applications. Users can pick and choose from hand-crafted ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... on foundational and sustainable systems change designed to further positively impact the health ... Board of Trustees has long considered it our duty to seriously consider releasing ...
Breaking Medicine News(10 mins):
(Date:2/19/2017)... , Feb. 19, 2017  nThrive™, an ... cycle portfolio and thought leadership at the 2017 ... a category leader award from KLAS. ... discussion focused on how market trends shape the ... particularly a sophisticated, comprehensive Patient Access solution. The ...
(Date:2/19/2017)... SAN FRANCISCO and ORLANDO, Fla. ... (Nasdaq: NKTR ) today announced that positive ... NKTR-214, in patients with renal cell carcinoma (RCC) were ... immuno-stimulatory therapy designed to expand specific cancer-fighting T cells ... tumor micro-environment and increase expression of PD-1 on these ...
(Date:2/18/2017)... -- Research and Markets has announced the addition of the ... ... comprehensive analytics for the US, Canada , ... , Latin America , and Rest of World. Annual ... a six-year historic analysis is provided for these markets. Market data and ...
Breaking Medicine Technology: